- Home
- FBIO vs RNTX Comparison
FBIO vs RNTX Comparison
Compare FBIO & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBIO
- RNTX
- Stock Information
- Founded
- FBIO 2006
- RNTX 2001
- Country
- FBIO United States
- RNTX United States
- Employees
- FBIO N/A
- RNTX N/A
- Industry
- FBIO Biotechnology: Pharmaceutical Preparations
- RNTX Biotechnology: Pharmaceutical Preparations
- Sector
- FBIO Health Care
- RNTX Health Care
- Exchange
- FBIO Nasdaq
- RNTX Nasdaq
- Market Cap
- FBIO 49.1M
- RNTX 40.3M
- IPO Year
- FBIO N/A
- RNTX N/A
- Fundamental
- Price
- FBIO $1.89
- RNTX $1.86
- Analyst Decision
- FBIO Strong Buy
- RNTX
- Analyst Count
- FBIO 3
- RNTX 0
- Target Price
- FBIO $21.00
- RNTX N/A
- AVG Volume (30 Days)
- FBIO 178.7K
- RNTX 52.1K
- Earning Date
- FBIO 05-15-2025
- RNTX 05-15-2025
- Dividend Yield
- FBIO N/A
- RNTX N/A
- EPS Growth
- FBIO N/A
- RNTX N/A
- EPS
- FBIO N/A
- RNTX N/A
- Revenue
- FBIO $57,784,000.00
- RNTX N/A
- Revenue This Year
- FBIO $63.20
- RNTX N/A
- Revenue Next Year
- FBIO $66.70
- RNTX N/A
- P/E Ratio
- FBIO N/A
- RNTX N/A
- Revenue Growth
- FBIO N/A
- RNTX N/A
- 52 Week Low
- FBIO $1.33
- RNTX $1.35
- 52 Week High
- FBIO $2.89
- RNTX $4.40
- Technical
- Relative Strength Index (RSI)
- FBIO 60.90
- RNTX N/A
- Support Level
- FBIO $1.66
- RNTX N/A
- Resistance Level
- FBIO $1.96
- RNTX N/A
- Average True Range (ATR)
- FBIO 0.11
- RNTX 0.00
- MACD
- FBIO 0.01
- RNTX 0.00
- Stochastic Oscillator
- FBIO 80.56
- RNTX 0.00
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.